Peroxisome proliferator-activated receptor γ agonists as neuroprotective agents

Drug News and Perspectives

Volumn 23, Issue 4, 2010, Pages 241-256

  Kaundal, Ravinder K ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CIGLITAZONE; DARGLITAZONE; DIZOCILPINE; GELATINASE B; L 796449; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; NP 00111; NP 01138; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROSTAGLANDIN J2; ROSIGLITAZONE; STAT PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; WNT PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN ISCHEMIA; HUMANS; MATRIX METALLOPROTEINASE 9; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PPAR GAMMA;

EID: 77954589341     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.4.1437710     Document Type: Review

References (126)

1. Abdelrahman, M., Sivarajah, A., Thiemermann, C. Beneficial effects of PPAR- gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005, 65(4): 772-81.
2. Green, S. PPAR: a mediator of peroxisome proliferator action. Mutat Res 1995, 333(1-2): 101-9.
3. Bordet, R., Ouk, T., Petrault, O. et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006, 34(Pt 6): 1341-6.
4. Heneka, M.T., Landreth, G.E. PPARs in the brain. Biochim Biophys Acta 2007, 1771(8): 1031-45.
5. Dhar, A., Kaundal, R.K., Sharma, S.S. Neuroprotective effects of FeTMPyP: a peroxynitrite decomposition catalyst in global cerebral ischemia model in gerbils. Pharmacol Res 2006, 54(4): 311-6.
6. Kaundal, R.K., Shah, K.K., Sharma, S.S. Neuroprotective effects of NU1025, a PARP ?inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci 2006, 79(24): 2293-302.
7. Sharma, S.S., Gupta, S. Neuroprotective effect of MnTMPyP, a superoxide dismutase/catalase mimetic in global cerebral ischemia is mediated through reduction of oxidative stress and DNA fragmentation. Eur J Pharmacol 2007, 561(1-3): 72-9.
8. Sharma, S.S., Kaundal, R.K. Neuroprotective effects of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), an antioxidant in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Neurol Res 2007, 29(3): 304-9.
9. Sharma, S.S., Munusamy, S., Thiyagarajan, M., Kaul, C.L. Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate-ribose) polymerase inhibitor alone and in combination in rats with focal cerebral ischemia. J Neurosurg 2004, 101(4): 669-75.
10. Thiyagarajan, M., Kaul, C.L., Sharma, S.S. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats. Br J Pharmacol 2004, 142(5): 899-911. (Pubitemid 38998103)
11. Mehta, S.L., Manhas, N., Raghubir, R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007, 54(1): 34-66. (Pubitemid 46498164)
12. Cheng, Y.D., Al-Khoury, L., Zivin, J.A. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004, 1(1): 36-45. (Pubitemid 46589340)
13. Culman, J., Zhao, Y., Gohlke, P., Herdegen, T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007, 28(5): 244-9.
14. Ji, S., Kronenberg, G., Balkaya, M., Farber, K., Gertz, K., Kettenmann, H., Endres, M. Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome. Exp Neurol 2009, 216(2): 321-8.
15. Allahtavakoli, M., Moloudi, R., Arababadi, M.K., Shamsizadeh, A., Javanmardi, K. Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat. Brain Res 2009, 1271: 121-7.
16. Sundararajan, S., Gamboa, J.L., Victor, N.A., Wanden, E.W., Lust, W.D., Landreth, G.E. Peroxisome proliferator-activated receptor- gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005, 130(3): 685-96.
17. Shimazu, T., Inoue, I., Araki, N. et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005, 36(2): 353-9.
18. Zhao, Y., Patzer, A., Herdegen, T., Gohlke, P., Culman, J. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 2006, 20(8): 1162-75.
19. Collino, M., Aragno, M., Mastrocola, R. et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006, 530(1-2): 70-80. (Pubitemid 43037126)
20. Patzer, A., Zhao, Y., Stock, I., Gohlke, P., Herdegen, T., Culman, J. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci 2008, 28(9): 1786-94.
21. Kaundal, R.K., Iyer, S., Kumar, A., Sharma, S.S. Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. J Pharmacol Sci 2009, 109(3): 361-7.
22. Lee, S.R., Kim, H.Y., Hong, J.S., Baek, W.K., Park, J.W. PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem Biophys Res Commun 2009, 380(1): 17-21.
23. Pereira, M.P., Hurtado, O., Cardenas, A. et al. Rosiglitazone and 15-deoxy-Delta12,14- prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006, 26(2): 218-29.
24. Luo, Y., Yin, W., Signore, A.P. et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006, 97(2): 435-48.
25. Chu, K., Lee, S.T., Koo, J.S. et al. Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res 2006, 1093(1): 208-18.
26. Chen, S.D., Wu, H.Y., Yang, D.I. et al. Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2. Biochem Biophys Res Commun 2006, 351(1): 198-203.
27. Tureyen, K., Kapadia, R., Bowen, K.K., Satriotomo, I., Liang, J., Feinstein, D.L., Vemuganti, R. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007, 101(1): 41-56. (Pubitemid 46426485)
28. Wu, J.S., Cheung, W.M., Tsai, Y.S. et al. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 2009, 119(8): 1124-34.
29. Sobrado, M., Pereira, M.P., Ballesteros, I. et al. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 2009, 29(12): 3875-84.
30. Allahtavakoli, M., Shabanzadeh, A., Roohbakhsh, A., Pourshanazari, A. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol 2007, 101(5): 309-14.
31. Kumari, R., Willing, L.B., Patel, S.D. et al. The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab 2010, 30(2): 352-60.
32. Lin, T.N., Cheung, W.M., Wu, J.S. et al. 15d- prostaglandin J2 protects brain from ischemia- reperfusion injury. Arterioscler Thromb Vasc Biol 2006, 26(3): 481-7.
33. Pereira, M.P., Hurtado, O., Cardenas, A. et al. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol 2005, 64(9): 797-805.
34. Victor, N.A., Wanderi, E.W., Gamboa, J. et al. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006, 24(6): 1653-63. (Pubitemid 44427534)
35. Schmerbach, K., Scheie, J.H., Krikov, M. et al. Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. Brain Res 2008, 1208: 225-33.
36. Kapadia, R., Yi, J.H., Vemuganti, R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008, 13: 1813-26. (Pubitemid 351599735)
37. Zhao, X., Strong, R., Zhang, J. et al. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 2009, 29(19): 6186-95.
38. Zhao, Y., Patzer, A., Gohlke, P., Herdegen, T., Culman, J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 2005, 22(1): 278-82. (Pubitemid 41059994)
39. Park, E.J., Park, S.Y., Joe, E.H., Jou, I. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 2003, 278(17): 14747-52.
40. Satriotomo, I., Bowen, K.K., Vemuganti, R. JAK2 and STAT3 activation contributes to neuronal damage following transient focal cerebral ischemia. J Neurochem 2006, 98(5): 1353-68.
41. Rosa, A.O., Egea, J., Martinez, A., Garcia, A.G., Lopez, M.G. Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors. Exp Neurol 2008, 212(1): 93-9.
42. Ou, Z., Zhao, X., Labiche, L.A., Strong, R., Grotta, J.C., Herrmann, O., Aronowski, J. Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2-mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 2006, 1096(1): 196-203.
43. Schock, S.C., Xu, J., Duquette, P.M. et al. Rescue of neurons from ischemic injury by peroxisome proliferator-activated receptor- gamma requires a novel essential cofactor LMO4. J Neurosci 2008, 28(47): 12433-44.
44. Mattiasson, G., Sullivan, P.G. The emerging functions of UCP2 in health, disease, and therapeutics. Antioxid Redox Signal 2006, 8(1-2): 1-38.
45. Lee, K.J., Jang, Y.H., Lee, H., Yoo, H.S., Lee, S.R. PPARgamma agonist pioglitazone reduces [corrected] neuronal cell damage after transient global cerebral ischemia through matrix metalloproteinase inhibition. Eur J Neurosci 2008, 27(2): 334-42.
46. Wang, C.X., Ding, X., Noor, R., Pegg, C., He, C., Shuaib, A. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 2009, 29(10): 1683-94.
47. Sharma, S.S., Kaundal, R.K. Targeting molecular pathways in stroke. In: Ray, A., Gulati, K. (Eds.). Current Trends in Pharmacology. I.K. International Publishing House Pvt. Ltd.: New Delhi, 2007, 311-26.
48. Sharma, S.S., Thiyagarajan, M. Molecular mechanisms of cerebral ischemia. In: Thakur, M.K., Prasad, S. (Eds.). Molecular and Cellular Neurobiology. 1st edition. Narosa Publishing House: New Delhi, 2005, 191-202.
49. Fong, W.H., Tsai, H.D., Chen, Y.C., Wu, J.S., Lin, T.N. Anti-apoptotic actions of PPAR- gamma against ischemic stroke. Mol Neurobiol 2010, Advance publication.
50. Fuenzalida, K., Quintanilla, R., Ramos, P. et al. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007, 282(51): 37006-15.
51. Combs, C.K., Johnson, D.E., Karlo, J.C., Cannady, S.B., Landreth, G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000, 20(2): 558-67.
52. Luna-Medina, R., Cortes-Canteli, M., Alonso, M., Santos, A., Martinez, A., Perez-Castillo, A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator- activated receptor gamma activation. J Biol Chem 2005, 280(22): 21453-62.
53. Heneka, M.T., Landreth, G.E., Feinstein, D.L. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann Neurol 2001, 49(2): 276. (Pubitemid 32158009)
54. in t' Veld, B.A., Ruitenberg, A., Hofman, A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001, 345(21): 1515-21.
55. Daynes, R.A., Jones, D.C. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2(10): 748-59.
56. Van Dam, D., Coen, K., De Deyn, P. Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. J Psychopharmacol 2010, 24(3): 383-8.
57. Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L. et al. Acute treatment with the PPARgamma agonist pioglitazone and Ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128(Pt 6): 1442-53. (Pubitemid 40826196)
58. Sastre, M., Dewachter, I., Rossner, S. et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 2006, 103(2): 443-8. (Pubitemid 43122420)
59. Pedersen, W.A., McMillan, P.J., Kulstad, J.J., Leverenz, J.B., Craft, S., Haynatzki, G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006, 199(2): 265-73.
60. Woster, A.P., Combs, C.K. Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. J Neurochem 2007, 103(1): 67-76.
61. Heneka, M.T., Klockgether, T., Feinstein, D.L. Peroxisome proliferator-activated receptor- gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000, 20(18): 6862-7.
62. Xu, J., Barger, S.W., Drew, P.D. The PPAR- gamma agonist 15-deoxy-delta-prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: Potential relevance to Alzheimer's disease. PPAR Res 2008, 2008: 349185.
63. Yan, Q., Zhang, J., Liu, H. et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003, 23(20): 7504-9.
64. Camacho, I.E., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D., De Strooper, B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 2004, 24(48): 10908-17.
65. Pedersen, W.A., Flynn, E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2004, 17(3): 500-6.
66. Watson, G.S., Cholerton, B.A., Reger, M.A. et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005, 13(11): 950-8.
67. Risner, M.E., Saunders, A.M., Altman, J.F. et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006, 6(4): 246-54.
68. Strum, J.C., Shehee, R., Virley, D. et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007, 11(1): 45-51. (Pubitemid 46376708)
69. Craft, S., Asthana, S., Schellenberg, G. et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to opolipoprotein-E genotype. Ann N Y Acad Sci 2000, 903: 222-8.
70. Craft, S., Asthana, S., Schellenberg, G. et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 1999, 70(2): 146-52.
71. Kuusisto, J., Koivisto, K., Mykkanen, L. et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997, 315(7115): 1045-9.
72. Sastre, M., Dewachter, I., Landreth, G.E., Willson, T.M., Klockgether, T., van Leuven, F., Heneka, M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003, 23(30): 9796-804.
73. d'Abramo, C., Massone, S., Zingg, J.M. et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 2005, 391(Pt 3): 693-8.
74. Andrews, R.C., Walker, B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999, 96(5): 513-23.
75. Green, K.N., Billings, L.M., Roozendaal, B., McGaugh, J.L., LaFerla, F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 2006, 26(35): 9047-56.
76. Inestrosa, N.C., Godoy, J.A., Quintanilla, R.A., Koenig, C.S., Bronfman, M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid myodegeneration: role of Wnt signaling. Exp Cell Res 2005, 304(1): 91-104. (Pubitemid 40227422)
77. Emilien, G., Maloteaux, J.M., Geurts, M., Hoogenberg, K., Cragg, S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999, 84(2): 133-56. (Pubitemid 29488548)
78. Hirsch, E.C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., Michel, P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003, 991: 214-28.
79. Hirsch, E.C., Hunot, S., Hartmann, A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005, 11 Suppl 1: S9-S15.
80. Breidert, T., Callebert, J., Heneka, M.T., Landreth, G., Launay, J.M., Hirsch, E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002, 82(3): 615-24.
81. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J., Schulz, J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004, 88(2): 494-501. (Pubitemid 38084565)
82. Hunter, R.L., Choi, D.Y., Ross, S.A., Bing, G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008, 432(3): 198-201.
83. Xing, B., Xin, T., Hunter, R.L., Bing, G. Pioglitazone inhibition of lipopolysaccharide- induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008, 5: 4. (Pubitemid 351757069)
84. Kumar, P., Kaundal, R.K., More, S., Sharma, S.S. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 2009, 197(2): 398-403.
85. Hunter, R.L., Dragicevic, N., Seifert, K. et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007, 100(5): 1375-86.
86. Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E., Carta, A.R. PPAR- gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009, 29(5): 954-63.
87. Kim, E.J., Kwon, K.J., Park, J.Y., Lee, S.H., Moon, C.H., Baik, E.J. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 2002, 941(1-2): 1-10.
88. Jung, T.W., Lee, J.Y., Shim, W.S. et al. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Biophys Res Commun 2006, 340(1): 221-7.
89. Xing, B., Liu, M., Bing, C Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J Neuroimmunol 2007, 192(1-2): 89-98.
90. Andrews, Z.B., Horvath, B., Barnstable, C.J. et al. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J Neurosci 2005, 25(1): 184-91.
91. Conti, B., Sugama, S., Lucero, J. et al. Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyltetrahydropyridine toxicity. J Neurochem 2005, 93(2): 493-501.
92. Andrews, Z.B., Rivera, A., Elsworth, J.D. et al. Uncoupling protein-2 promotes nigrostriatal dopamine neuronal function. Eur J Neurosci 2006, 24(1): 32-6.
93. Miranda, E.J., Mclntyre, I.M., Parker, D.R., Gary, R.D., Logan, B.K. Two deaths attributed to the use of 2,4-dinitrophenol. J Anal Toxicol 2006, 30(3): 219-22.
94. Wiley, S.E., Murphy, A.N., Ross, S.A., van der Geer, P., Dixon, J.E. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci U S A 2007, 104(13): 5318-23.
95. Colca, J.R., McDonald, W.G., Waldon, D.J. et al. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004, 286(2): E252-60.
96. Quinn, L.P., Crook, B., Hows, M.E. et al. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol 2008, 154(1): 226-33.
97. Compston, A., Coles, A. Multiple sclerosis. Lancet 2002, 359(9313): 1221-31.
98. Martin, R., McFarland, H.F., McFarlin, D.E. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992, 10: 153-87.
99. Lassmann, H., Bruck, W., Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001, 7(3): 115-21.
100. Van Eldik, L.J., Akama, K.T., Petrova, T.V. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy- Delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A 1999, 96(8): 4668-73.
101. Van Eldik, L.J., Petrova, T.V., Koppal, T. Cyclopentenone prostaglandin 15-deoxy- Delta(12,14)-prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. Brain Res 2000, 867(1-2): 115-21.
102. Minghetti, L., Levi, G., Bernardo, A. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 2000, 12(7): 2215-23.
103. Xu, J., Drew, P.D. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 2007, 178(3): 1904-13.
104. Clark, R.B., Bishop-Bailey, D., Estrada- Hernandez, T., Hla, T., Puddington, L., Padula, S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000, 164(3): 1364-71.
105. Diab, A., Deng, C., Smith, J.D. et al. Peroxisome proliferator-activated receptor- gamma agonist 15-deoxy-Delta(12,14)- prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168(5): 2508-15.
106. Kielian, T., McMahon, M., Bearden, E.D., Baldwin, A.C., Drew, P.D., Esen, N. S. aureus- dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Delta12,14- prostaglandin J2 (15d-PGJ2). J Neurochem 2004, 90(5): 1163-72.
107. Niino, M., Iwabuchi, K., Kikuchi, S. et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol 2001, 116(1): 40-8.
108. Feinstein, D.L., Galea, E., Gavrilyuk, V. et al. Peroxisome proliferator-activated receptor- gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002, 51(6): 694-702.
109. Trebst, C., Ransohoff, R.M. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 2001, 58(12): 1975-80.
110. Kintscher, U., Goetze, S., Wakino, S. et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2000, 401(3): 259-70.
111. Marx, N., Mach, F., Sauty, A. et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000, 164(12): 6503-8.
112. Natarajan, C., Muthian, G., Barak, Y., Evans, R.M., Bright, J.J. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol 2003, 171(11): 5743-50.
113. Heneka, M.T., Moric, E., Schmidt, M., Sastre, M., Feinstein, D.L., Schmidt, M. Anti-inflammatory and antiproliferative actions of PPAR- gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 2004, 75(3): 478-85.
114. Schmidt, S., Moric, E., Schmidt, M., Sastre, M., Feinstein, D.L., Heneka, M.T. Anti-inflammatory and antiproliferative actions of PPAR- gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 2004, 75(3): 478-85.
115. Klotz, L., Schmidt, M., Giese, T., Sastre, M., Knolle, P., Klockgether, T., Heneka, M.T. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005, 175(8): 4948-55.
116. Pershadsingh, H.A., Heneka, M.T., Saini, R., Amin, N.M., Broeske, D.J., Feinstein, D.L. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 2004, 1(1): 3.
117. Kiaei, M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res 2008, 2008: 418765.
118. Mosley, R.L., Gendelman, H.E. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp Neurol 2010, 222(1): 1-5.
119. Kiaei, M., Kipiani, K., Chen, J., Calingasan, N.Y., Beal, M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005, 191(2): 331-6.
120. Schutz, B., Reimann, J., Dumitrescu-Ozimek, L. et al. The oral antidiabetic pioglitozone protects from neurodegenerotion and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005, 25(34): 7805-12.
121. Shibata, N., Yamamoto, T., Hiroi, A., Omi, Y., Kato, Y., Kobayashi, M. Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis. Neuropathology 2009, Advance publication.
122. Shibata, N., Kawaguchi-Niida, M., Yamamoto, T., Toi, S., Hirano, A., Kobayashi, M. Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology 2008, 28(4): 387-98.
123. Yu, X., Shao, X.G., Sun, H., Li, Y.N., Yang, J., Deng, Y.C., Huang, Y.G. Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Res 2008, 1200: 146-58.
124. Zhao, X., Ou, Z., Grotta, J.C., Waxham, N., Aronowski, J. Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res 2006, 1073-1074: 460-9.
125. Hyong, A., Jadhav, V., Lee, S., Tong, W., Rowe, J., Zhang, J.H., Tang, J. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 2008, 1215: 218-24.
126. Churi, S.B., Abdel-Aleem, O.S., Tumber, K.K., Scuderi-Porter, H., Taylor, B.K. Intrathecal rosiglitazone acts at peroxisome proliferator- activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain 2008, 9(7): 639-49.